STAT3 and cancer: Indeed, the JAK inhibitors INCB16562, AZD1480, and tofacitinib (CP-690550) have potently blocked STAT3 signaling, suppressed cancer cell proliferation, or induced apoptosis in vitro and tumor growth in vivo [123,124,125].